Search results for: Multi-Indication Medicines
Filter search results
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
…approach for assessing regenerative medicines, but rather to test whether regenerative medicines could fit into the existing pathway developed for conventional medicines. The authors suggest a more interesting question would…
Why do we expect obesity medicines to work differently?
5 March 2026
…the study, who emphasises, “This [weight gain] isn’t a failing of the medicines – it reflects the nature of obesity as a chronic, relapsing condition.” The World Health Organization describes…
Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate
25 June 2026
The German puzzle Discussion of Most-Favoured-Nation (MFN) drug pricing has converged on a single question: can the United States persuade other wealthy countries to pay more for medicines, and so…
Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax
24 October 2018
…Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS. London: Office of Health Economics. Sampson, C., O’Neill, P. and Lorgelly, P. (2018) The Impact of New Medicines…
The Future of Global Health Procurement: Issues around Pricing Transparency
1 March 2019
…of medicines by Middle and Low Income Countries. Will making prices publicly available make procurement more efficient and cost-effective medicines more accessible? This OHE Research Paper focuses on the role…
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
…to downstream access, which aims to accelerate patient access to innovative medicines through a collaborative approach involving multiple regulatory and HTA bodies. ILAP provides pharmaceutical companies with access to various…
Update: Value-Based Pricing in the UK
11 January 2011
…the pricing of branded medicines’ — that provides a first indication of how VBP may replace the PPRS. The DH consultation sets out a ‘QALY-plus’ approach for drug pricing for branded…
New Paper in Quality of Life Research – Can Patients’ Self-Reported Pain be Compared and Aggregated in Multi-Country Studies?
30 March 2017
…in multi-country studies A new journal article entitled “An exploration of differences between Japan and two European countries in self-reporting and valuation of pain and discomfort on the EQ-5D” has…
OHE Lunchtime Seminar: Is Hypothecation the Way to Raise the Money for the “multi-year” Funding Settlement That the NHS Has Been Promised?
4 July 2018
OHE Lunchtime Seminar with Nicholas Timmins on ‘Is hypothecation the way to raise the money for the “multi-year” funding settlement that the NHS has been promised?’ To be held on…